Table 4.
Association of baseline characteristics (major ECG abnormalities, demographics, and clinical characteristics) with incident cardiovascular events
Hazard ratio (95% Confidence Interval) | P | |
---|---|---|
Major ECG abnormality | ||
Abnormality present | 1.83 (1.12, 2.97) | 0.015 |
Abnormality absent, other abnormality present | 1.13 (0.78, 1.62) | 0.51 |
No abnormalities | Ref. | - |
Treatment Group (drug conservative vs. viral suppression) | 1.43 (1.03, 1.99) | 0.032 |
Age (year) | 1.05 (1.03, 1.07) | <0.001 |
Gender (female vs. male) | 0.60 (0.38, 0.96) | 0.032 |
Race | ||
Black | 1.03 (0.70, 1.50) | 0.90 |
Asian | 0.45 (0.06, 3.29) | 0.43 |
Other | 0.79 (0.43, 1.45) | 0.45 |
White | Ref | - |
Smoking Status | ||
Current | 1.82 (1.19, 2.77) | 0.006 |
Past | 1.17 (0.73, 1.87) | 0.51 |
Never | Ref | - |
Total/HDL Cholesterol Ratio | 1.04 (1.00, 1.09) | 0.034 |
Baseline body mass index | 1.00 (0.97, 1.04) | 0.84 |
Diabetes (yes vs. no) | 1.83 (1.16, 2.89) | 0.010 |
Use of blood pressure-lowering drugs | 2.00 (1.39, 2.88) | <0.001 |
Use of lipid lowering drugs | 1.04 (0.69, 1.58) | 0.84 |
Years since HIV diagnosis | 1.00 (0.97, 1.04) | 0.91 |
Baseline CD4 (per 100) | 1.03 (0.97, 1.10) | 0.35 |
Baseline HIV-RNA and antiretroviral status | ||
Off Antiretroviral therapy | 1.29 (0.76, 2.21) | 0.35 |
On Antiretroviral therapy, HIV-RNA ≤ 400 | 0.99 (0.64, 1.53) | 0.95 |
On Antiretroviral therapy, HIV-RNA > 400 | Ref. | - |